A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

496

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Fuzuloparib , Abiraterone acetate and Prednisone
DRUG: Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Sponsor

Jiangsu HengRui Medicine Co., Ltd.